Treating patients with B-ALL can be challenging but we have made accessing all the information you need about BLINCYTO® in order to optimise your patient outcomes easy with this comprehensive resource hub.
BLINCYTO® is indicated for the treatment of:1
BLINCYTO® is a bispecific T-cell engager (BiTE®) antibody construct that binds to CD19 on the surface of cells of B-lineage origin, and CD3 expressed on the surface of T-cells.1-3 BLINCYTO® mediates the formation of a bridge in the form of an immune synapse between the T-cell and malignant B-cell.1-3
Subsequent lytic proteins released by the T-cell induce target cell death.1-3
BLINCYTO® – an immunotherapy that uses BiTE® technology to engage the body’s own immune system to target malignant cells1-4
Accessing on the PBS
BLINCYTO® is available on the PBS for the treatment of MRD+ B-ALL and R/R B-ALL via an AUTHORITY prescription.5
BLINCYTO® is the only PBS-listed therapy for the treatment of MRD+ B-ALL.5
BLINCYTO® vials MUST be purchased direct from Amgen via the DHL Customer Service Team using a dedicated account set up solely for this purpose.
Use of BLINCYTO® should be restricted to physicians experienced in the treatment of haematological malignancies.
Please see summaries of the key BLINCYTO® studies below. If you are interested in receiving slides for educational purposes please contact Amgen Med Info here.
Adult Ph- R/R B-ALL
Phase III TOWER study7
Kantarjian H, et al. N Engl J Med. 2017;376:836–847.Download
Adult Ph+ R/R B-ALL
Phase II ALCANTARA study8
Martinelli G et al. J Clin Oncol 2017;35:1795–802.Download
Adult MRD+ B-ALL
Phase II BLAST study9
Gökbuget N et al. Blood 2018;131:1522–31.Download
Adverse events may be clinically managed with treatment interruption and/or dose adjustments1
BLINCYTO® can be restarted when the AE is resolved or no more than Grade 1 (mild), depending on the type of AE.1
Warning: The following have occurred in patients receiving BLINCYTO®:1
Interrupt or discontinue BLINCYTO® as recommended if any of these adverse events occur.1
Patient management resources
These guides have been developed for your patients with B-ALL who are treated with BLINCYTO® to help answer some of their questions about their condition and explain what their treatment may be like.